130306-02-4
130306-02-4 結(jié)構(gòu)式
基本信息
(E)-2'-DEOXY-2'-(FLUOROMETHYLENE) CYTIDINE
Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2'E)-
物理化學(xué)性質(zhì)
常見問題列表
Ribonucleotide reductase
Tezacitabine (0.01-10 μM; 24 hours; CCRF-SB, KG-1, Jurkat, COLO-205, MCF-7 and PC-3 cells) treatment induces the G1 and S-phase leaky block of the cell cycle.
Tezacitabine (0.01-10 μM; 24 hours; CCRF-SB, KG-1, Jurkat, COLO-205, MCF-7 and PC-3 cells) treatment apoptotic death of cells by the caspase 3/7 pathway in a concentration-dependent manner.
Tezacitabine has strong cytostatic and cytotoxic properties. Cytotoxic effect of Tezacitabine reveals not only as apoptosis, but also as a change in protein metabolism.
Cell Cycle Analysis
| Cell Line: | CCRF-SB, KG-1, Jurkat, COLO-205, MCF-7 and PC-3 cells |
| Concentration: | 0.01 μM, 0.1 μM, 1.0 μM, and 10 μM |
| Incubation Time: | 24 hours |
| Result: | Induced the G1 (at concentrations higher than 10 nM) and S-phase (at low concentration) leaky block of the cell cycle. |
Apoptosis Analysis
| Cell Line: | CCRF-SB, KG-1, Jurkat, COLO-205, MCF-7 and PC-3 cells |
| Concentration: | 0.01 μM, 0.1 μM, 1.0 μM, and 10 μM |
| Incubation Time: | 24 hours |
| Result: | Induced apoptotic death of cells by the caspase 3/7 pathway in a concentration-dependent manner. |
Tezacitabine (100 mg/kg; intraperitoneal injection; daily; female nude mice) treatment inhibits tumor growth in HCT 116 tumor xenografts.
| Animal Model: | Female nude mice (7-9-week-old) injected with HCT 116 cells |
| Dosage: | 100 mg/kg |
| Administration: | Intraperitoneal injection; daily; 14 days |
| Result: | Inhibited tumor growth in HCT 116 tumor xenografts. |